OncoHost
@OncoHost
Followers
928
Following
1K
Media
526
Statuses
1K
A technology company transforming the approach to #precisionmedicine for improved patient outcomes. PROphetNSCLC™ test now available in the US!
Binyamina & North Carolina
Joined October 2019
August 1 is #InternationalLungCancerDay. We stand with the global oncology community in advancing personalized care, earlier detection & better outcomes. Together, we push forward. #LungCancerAwareness #PrecisionOncology #NSCLC
0
0
0
Our Director of Scientific Affairs, Anna Manasherov, will attend Best of ASCO® 2025 Miami, joining oncology experts to explore the latest breakthroughs in cancer care. Let’s connect in Miami!. #BestofASCO #Oncology #PrecisionOncology #CancerResearch
0
0
0
We’re honored to be named Top Precision Oncology Solution for 2025 by Life Sciences Review! 🏆.Proud to see #PROphet recognized for redefining personalized cancer care through AI + proteomics. 🔗 Read more: #PrecisionOncology #CancerCare #Immunotherapy.
prnewswire.com
/PRNewswire/ -- OncoHost, a leader in precision oncology leveraging proteomics and AI to personalize cancer care, today announced its selection as the Top...
0
0
0
We're developing NeutroFlow — a point-of-care test using flow cytometry to predict immunotherapy response across 5 cancers. "Ly6Ehi neutrophils can be easily detected in any hospital." — Dr. Michal Harel. 🌐 Learn more: #Immunotherapy #Oncology.
neutroflow.com
NeutroFlow, an EIC Transition funded project aiming to develop and validate a point-of-care, flow cytometry-based diagnostic test that detects a novel cellular biomarker in the blood for predicting...
0
0
0
Your stage 4 #mNSCLC checklist:.✓ Confirm patient diagnosis.✓ Order PROphetNSCLC™ alongside NGS and PD-L1.✓ Plan 1L treatment. PROphetNSCLC™ provides valuable insights for treatment planning. Learn more:
oncohost.com
Easily order OncoHost's PROphet NSCLC test to gain valuable insights for personalized cancer treatment. Empowering better healthcare decisions.
0
0
0
Another reminder for UV Safety Month!. Protecting our skin from the sun’s harmful rays is essential, and July is the perfect time to raise awareness about UV safety. Stay safe and have a great summer!. #uvsafetymonth #skincancerawareness #skincancer #melanoma #ActNowLiveLonger.
0
0
0
OncoHost is attending the International Lung Cancer Congress in Huntington Beach, CA!. Catch our team on-site:.👨💼 Chris Dingman, CCO.👩💼 Isabelle Eyman, Regional Sales Director. Let’s connect on the future of NSCLC care. #ILCC2025 #LungCancer
0
0
0
Why do some patients resist immunotherapy?.🔍 Proteomics helps decode the answer. By analyzing protein patterns, it reveals biomarkers, immune cell activity & tumor microenvironment dynamics—unlocking new paths to overcome resistance. #Proteomics #Immunotherapy #CancerCare.
0
0
0
🔬 Meet PROphet® — our AI-powered platform using proteomics to predict & explain immunotherapy outcomes. From one blood sample 🩸, it reveals:.✔️ Likelihood of benefit.✔️ Reason for resistance.✔️ irAE risk ⚠️. #NSCLC #AIinOncology #Proteomics #CancerCare.
oncohost.com
Explore OncoHost's PROphet Technology, a cutting-edge precision oncology platform driving advancements in biomarkers for cancer treatment decisions.
0
0
0
🚨 The FDA has granted accelerated approval to datopotamab deruxtecan (Dato-DXd) for adults with locally advanced or metastatic EGFR-mutated NSCLC who’ve progressed after EGFR-targeted therapy and platinum chemo. #IndustryNews #NSCLC #LungCancer.
targetedonc.com
FDA accelerates approval of datopotamab deruxtecan for advanced EGFR-mutated NSCLC, offering new hope for previously treated patients.
0
0
0
Thank you @MLOnews for featuring our big win! 🏆. OncoHost is proud to be named a Gold Winner in the 2025 Merit Awards for R&D, recognizing our innovation behind the PROphet® platform. 🔗 #MeritAwards #PrecisionOncology #AIinHealthcare #Proteomics.
0
0
0
🚀 We’re live!. Visit — the official site for NeutroFlow, a new OncoHost-led project funded by a €2.5M EIC Grant to advance a novel biomarker predicting immunotherapy response across 5 cancers. #PrecisionOncology #EICTransition #CancerResearch.
neutroflow.com
NeutroFlow, an EIC Transition funded project aiming to develop and validate a point-of-care, flow cytometry-based diagnostic test that detects a novel cellular biomarker in the blood for predicting...
0
0
0
📍 Headed to the New Orleans Summer Cancer Meeting (NOSCM) this week?. Stop by Booth #67 to meet the OncoHost team and learn how our AI-powered PROphet® platform is helping oncologists personalize immunotherapy with confidence. #NOSCM2025 #OncologyInnovation #PrecisionOncology
0
0
0
Immunotherapy is powerful—but irAEs remain a real risk. PROphetirAE™ helps predict severe toxicity before treatment starts. As our CTO Dr. Yehonatan Elon says:.“It’s time we bring the same precision to predicting harm.”. 🔗 #irAE #PrecisionOncology.
technologynetworks.com
Today, our approach to irAE management is predominantly reactive. Clinical guidelines, while increasingly robust, are designed to detect and treat toxicity after it arises. This framework, though...
0
0
0
We’re honored to see our recent R&D recognition featured by European Pharmaceutical Manufacturer! 🏆. 📖 Read the feature: #PrecisionOncology #Proteomics #MeritAwards #R&DExcellence.
pharmaceuticalmanufacturer.media
OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, has been named a Gold Winner in the 2025 Merit Awards for Business in the Research and...
0
0
0
🚨 Transforming #NSCLC treatment!. Our PROphetNSCLC™ blood test delivers unmatched accuracy, predicts clinical benefit & survival, and empowers oncologists to make personalized, data-driven decisions 🌟. 🔗 Learn more: #precisiononcology #AI #proteomics.
oncohost.com
Explore OncoHost's home for cutting-edge precision oncology solutions, driving advancements in cancer care and personalized treatment strategies.
1
0
2
Every oncologist’s decision reshapes a future. PROphet® is the industry's first AI-powered composite biomarker. A clinically actionable predictive algorithm—delivering 1L immunotherapy treatment guidance to optimize your patients' outcomes. Your insights. Amplified. By PROphet®.
0
0
1
🏆 We’ve done it again!.OncoHost is a 2025 Merit Awards Gold Winner in R&D!. This recognition celebrates our AI-powered PROphet® platform, transforming cancer care by predicting treatment response & toxicity from a single blood test. #MeritAwards2025
0
0
0
Protecting our skin is a year-round responsibility. As the sun shines brighter, it's even more important for our health to protect ourselves from harmful #UV rays. #uvsafetymonth #sunsafesummer #melanoma #skincancerawareness.
0
0
0
🚀 Coming soon: PROphetRCC™ – our AI-driven blood test for renal cell carcinoma. Predict immunotherapy benefit and toxicity before treatment begins. A new era in RCC care is on the horizon. #RCC #PrecisionOncology #Immunotherapy.
0
0
0